Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Inside Moderna and Merck's cancer vaccine breakthrough
2+ week, 12+ hour ago (92+ words) Xavier Martinez, News Associate at The Wall Street Journal, breaks down Moderna’s mRNA ambitions, its pipeline beyond COVID-19 and the challenges ahead. Stephane Bancel, CEO of Moderna, was at a Lebanese restaurant celebrating a friend’s birthday late on Aug. 13 when…...
Melanoma Vaccine Data Breakthrough: Moderna Receives Fifth Analyst Upgrade in Five Days — BigGo Finance
2+ week, 2+ day ago (391+ words) U.S. biotech giant Moderna (MRNA) continues to ride a wave of momentum from clinical data on its melanoma mRNA cancer vaccine, prompting a notable shift in Wall Street analyst sentiment. Argus Research this week upgraded Moderna from "Hold" to "Buy," becoming…...
Immatics: 'Buy' On 1st Half 2027 Catalyst, Potential Label Expansion For Uveal Melanoma
2+ week, 5+ day ago (106+ words) Immatics: 'Buy' On Anzu-Cel 1st Half 2027 Catalyst And Potential Label Expansion For Uveal Melanoma Seeking Alpha - Immatics N.V. is rated "Buy," downgraded from "Strong Buy," due to partial partnership termination and pivotal trial dependency. - IMTX's investment thesis centers on anzu-cel [IMA203], a PRAME-directed…...
How the Merck/Moderna cancer vaccine works and possible barriers to wide use
2+ week, 5+ day ago (47+ words) Published on 08/25/2026 at 12:31 pm EDT Moderna Soars 129% for the Week | Closing Bell August 21, 2026 at 05:02 pm EDT Will Moderna Wake Up the Health Care Sector? Moderna and Merck & Co are the stocks of the day on Wall Street...
Moderna Added 45 Billion Dollars in a Day on a Melanoma Vaccine Result with No Effect Size Disclosed
2+ week, 5+ day ago (512+ words) Moderna and Merck reported that their personalized mRNA cancer vaccine succeeded in a Phase 3 melanoma trial. Moderna's market value rose by nearly $45 billion in a single session, with the two companies and rival BioNTech gaining around $92 billion collectively. Neither partner…...
Metastatic Melanoma Therapeutics Market Study Highlights How Industry Demand Is Evolving
3+ week, 2+ day ago (56+ words) openPR.com Metastatic Melanoma Therapeutics Market Study Highlights How Industry Demand Is Evolving Press release from: The Business Research Company Permanent link to this press release: You can edit or delete your press release Metastatic Melanoma Therapeutics Market Study Highlights…...
Merck Slips After 12.6% Cancer-Vaccine Surge
3+ week, 3+ day ago (226+ words) Profit-taking followed a record-setting rally sparked by the first successful Phase 3 trial of an mRNA cancer treatment. Oops, something went wrong U.S. markets close in 6m Merck Slips After 12.6% Cancer-Vaccine Surge This article first appeared on GuruFocus. Merck (NYSE:MRK), the pharmaceutical…...
Moderna's cancer vaccine hits key goal in melanoma trial with NYU Langone link
3+ week, 3+ day ago (677+ words) Moderna's cancer vaccine trial included one or more patients from NYU Langone Hospital — Long Island in Mineola. Credit: Newsday/Howard Schnapp A Long Island hospital helped pharmaceutical giants Moderna and Merck test an experimental personalized cancer vaccine that helped keep…...
Moderna Stock Skyrockets 177% After Positive Late-Stage Skin Cancer Vaccine Trial Results
3+ week, 3+ day ago (503+ words) 💥Build Your Research Hub Your Way.New users are invited to save 20% for a limited time @vladeep via Canva, @Sezeryadigar from Getty Images Signature via Canva Moderna (MRNA) stock exploded higher on Wednesday, jumping about 177% after Moderna and Merck announced…...
The bigger opportunity: beyond melanoma - Moderna???s Cancer Vaccine Breakthrough: What It Means for the Stock
3+ week, 3+ day ago (482+ words) Moderna and Merck’s personalised mRNA cancer vaccine has delivered positive results in a late-stage trial for melanoma, marking a major milestone for the technology beyond COVID-19 vaccines. The development sent Moderna shares sharply higher as investors reassessed the company’s long-term…...